申请人:Novo Nordisk A/S
公开号:US05260298A1
公开(公告)日:1993-11-09
Imidazotriazoloquinazoline compounds having the general formula ##STR1## wherein A together with the .alpha.-marked carbon atom and the .beta.-marked nitrogen atom is one of the groups ##STR2## cyano or CO.sub.2 R.sup.5, wherein R.sup.5 is H, alkyl, cycloalkyl, trifluoromethyl or alkoxymethyl; and R.sup.2, R.sup.3 and R.sup.4 independently are H, hydroxy, halogen, CN, alkyl, alkenyl, alkynyl, trifluoromethyl, alkoxy, dialkylaminoalkoxy, aralkoxy, aryloxy which may be substituted, acyclic amino group, or NR.sup.6 R.sup.7, wherein R.sup.6 and R.sup.7 independently are H or alkyl. The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, antipsychotics, antiemetics, or in improving the cognitive function of the brain of mammals, or as benzodiazepine antagonsists.
具有一般式##STR1##的咪唑三唑喹唑啉化合物,其中A与标记为α的碳原子和标记为β的氮原子之一是以下组之一##STR2##氰基或CO.sub.2R.sup.5,其中R.sup.5为H,烷基,环烷基,三氟甲基或烷氧甲基;而R.sup.2、R.sup.3和R.sup.4独立地为H,羟基,卤素,CN,烷基,烯基,炔基,三氟甲基,烷氧基,二烷基氨基烷氧基,芳基氧基,可被取代的芳基氧基,非环状氨基基团,或NR.sup.6R.sup.7,其中R.sup.6和R.sup.7独立地为H或烷基。这些化合物在心理药物制剂中作为抗癫痫药、抗焦虑药、催眠药、抗精神病药、抗恶心药、或用于改善哺乳动物大脑的认知功能,或作为苯二氮平拮抗剂。